Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-provided verdict/rationale states that ENTRESTO can cause fetal harm and that the label describes fetal/neonatal morbidity and death associated with renin-angiotensin system acting drugs in the 2nd/3rd trimesters, with guidance to consider alternatives and discontinue upon pregnancy detection; these points are supported by the supplied label text (5.1 and 8.1).
Category Scores
Accurate Statements
ENTRESTO can cause fetal harm when administered to a pregnant woman.
Supported by 5.1 Fetal Toxicity and 8.1 Pregnancy Risk Summary.
Use of drugs that act on the renin-angiotensin system during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death.
Supported by 5.1 Fetal Toxicity and 8.1 Pregnancy Risk Summary.
When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO.
Supported by 5.1 Fetal Toxicity and 8.1 Pregnancy Risk Summary.
Unsupported Statements
Contradictions
Important Omissions
The label’s detailed clinical considerations in 8.1 (e.g., oligohydramnios effects, serial ultrasound, fetal testing, neonatal monitoring for hypotension/oliguria/hyperkalemia, and potential need for support/dialysis) were not explicitly included in the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI content evaluated the pregnancy/fetal toxicity risk claim and concluded it is supported, matching the supplied label’s core warnings without introducing conflicting or incorrect risk minimization.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The response did not reproduce the label’s more granular pregnancy management and neonatal monitoring details from 8.1 Clinical Considerations.
Suggested Improvement
Include the specific clinical considerations (serial ultrasound, fetal testing as appropriate, neonatal monitoring parameters, and actions such as supporting BP/renal perfusion and possible dialysis/exchange transfusion) when summarizing the pregnancy risk claim.